12 Aug
2021

mRNA IP will be hot property beyond the pandemic

The versatility of mRNA-based medicine, and pressures on mRNA manufacturing, mean that a spate of IP-based deal-making in the space is likely to continue beyond the pandemic.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth